EGFR and lung adenocarcinoma: EGFR-Mut lung adenocarcinomas had a lower R-score than EGFR-WT ones in training dataset (−0.40 ± 0.50 vs. 0.05 ± 0.68, P = 0.000), which was confirmed in validation dataset (−0.37 ± 0.51 vs. 0.01 ± 0.0.58, P = 0.000) (Table 2).